Seminars in Oncology
Volume 32, Issue 2 , Pages 145-155, April 2005

Palliative chemotherapy: Historical perspective, applications, and controversies

  • Ilene Browner

      Affiliations

    • Divisions of Medical Oncology and Geriatric Medicine and Gerontology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD, USA
  • ,
  • Michael A. Carducci

      Affiliations

    • Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD, USA
    • Corresponding Author InformationAddress reprint requests to Michael A. Carducci, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CRB IM89, 1650 Orleans St, Baltimore, MD 21231-2410.

Despite advances in cancer detection and treatment, cancer continues to be a major public health burden in the United States, and patients with advanced or refractory cancers carry much of this burden. The primary goal of cancer treatment is cure. However, most patients with advanced, metastatic, or recurrent disease do not benefit from this intent. Recent research studies have documented the role of chemotherapy in providing symptom control, preventing complications, prolonging life, and improving quality of life (QOL) in patients with incurable cancers. Although chemotherapy under these conditions is palliative, patients receiving chemotherapy or participating in research trials are excluded from receiving much needed palliative services, such as Hospice, based on current definitions, limitations, and models of palliative care. Application of palliative services on a continuum from the time of diagnosis through the end of life (EOL) has been recognized as beneficial in the treatment of patients with terminal diseases and has been addressed through trials assessing mixed management models, providing palliative and therapeutic options.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Simultaneous Care Grant NIH I-R25 CA95260 (M.A.C.), and ASCO-Hartford Association Geriatric-Oncology Fellowship Training Grant (I.B.).

PII: S0093-7754(04)00571-8

doi:10.1053/j.seminoncol.2004.11.014

Seminars in Oncology
Volume 32, Issue 2 , Pages 145-155, April 2005